Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evasayil TM: Spesolimab in Netherton syndrome
2022-501104-10-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in Netherton syndrome (NS) comparing Spesolimab with Placebo (2 arms). Primary endpoint: IASI response. Started Jun 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on 2022-501104-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501104-10-00.